New Phase 3 data with aprocitentan to be presented at the European Society of Hypertension Annual Meeting 202

Allschwil, Switzerland – June 23, 2023 Idorsia Ltd (SIX: IDIA) today announced that further data for aprocitentan, Idorsia’s investigational dual endothelin receptor antagonist evaluating the

Related Keywords

Australia ,Japan ,Switzerland ,Italy ,Allschwil ,Switzerland General ,Milan ,Lombardia ,United States ,Swiss ,American ,Andrewc Weiss ,Arthurc Corcoran ,Markus Schlaich ,Idorsia Pharmaceuticals Ltd ,Head Of Investor Relations Corporate Communications ,Swiss Exchange ,International Society Of Hypertension ,Hypertension Council ,European Society Of Cardiology ,Idorsia Ltd ,American Heart Association ,European Society Of Hypertension ,European Society ,European Meeting ,Cardiovascular Protection ,Yellow Hall ,Uncontrolled Hypertension ,Late Breaking Science ,Scientific Sessions ,International Society ,Executive Committee ,Management Board ,Measurement Month ,Hypertension Australia ,High Blood Pressure ,Folkow Award ,Editorial Board ,Vice President ,Investor Relations ,Pharmaceuticals Ltd ,